• New topical therapies should be assessed in the context of well-designed clinical trials comparing them with topical mechlorethamine.
• The role of new immunotherapies and retinoids in early stage (IB/IIA) disease should involve comparative RCTs with standard therapies such as PUVA.
• TSEB therapy with or without adjuvant immunotherapy and chemotherapy should be reserved for patients with late stages of disease, preferably in the context of clinical trials.
• There is an urgent need for more effective therapy for late-stage disease and this should be based on appropriate RCTs involving new immunotherapies, adjuvants, single- and multi-agent chemotherapies and both (mini)allogeneic and autologous transplants in selected individuals.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.